Search results
Results From The WOW.Com Content Network
The 1965 Corvette Sting Ray became ferocious with the mid-year debut of the "Big-Block" 396 cu in (6,490 cc) engine producing 425 hp (317 kW). Ultimately, this spelled the end for the Rochester fuel injection system, as the carbureted 396ci/425hp option cost $292.70 to the fuel injected 327ci/375hp's $538.00.
The Chevrolet Corvette is a line of American two-door, two-seater sports cars manufactured and marketed by General Motors under the Chevrolet marque since 1953. [ 1][ 2] Throughout eight generations, indicated sequentially as C1 to C8, the Corvette is noted for its performance, distinctive styling, lightweight fiberglass or composite bodywork ...
The National Corvette Museum showcases the Chevrolet Corvette, an American sports car that has been in production since 1953. It is located in Bowling Green, Kentucky, off Interstate 65 's Exit 28 and near General Motors ' Bowling Green Assembly Plant, where Corvettes are manufactured. It was constructed in 1994, and opened to the public in ...
You can find instant answers on our AOL Mail help page. Should you need additional assistance we have experts available around the clock at 800-730-2563.
Grant, a 63-year-old former sales professional, was looking for a smaller-scale place with access to a larger city, and the coastal town of Sitges in Catalonia is ideally located less than an hour ...
Chevrolet Corvette SS. The Corvette Stingray Racer is a sports racing car and concept car that debuted in 1959. The car was developed in the styling studios at General Motors (GM) at the behest of Bill Mitchell, GM Vice President of styling. The design was based on a sketch by designer Pete Brock, and was further developed by Larry Shinoda.
If you were born on Leap Day 1924, you would be 100 years old, or 25 in Leap Day years. The year must be evenly divisible by 4. If the year can be evenly divided by 100, it is not a leap year ...
If approved, Pfizer's hemophilia A gene therapy will compete with BioMarin Pharmaceutical's one-time treatment Roctavian, which was approved in the U.S. last year and is priced at $2.9 million.